Our story
Built to deliver smarter therapies
Unicycive was founded in 2016 to accelerate healthcare innovation in overlooked areas like kidney disease. While traditional drug development often takes many years, our team is built to move faster, identifying undervalued assets and turning them into best-in-class therapies.
Our focus is on closing urgent gaps in kidney care—a space where innovation lags despite the growing burden of chronic kidney disease.
In 2018, we licensed our first two technologies, oxylanthanum carbonate (OLC) and UNI-494. Backed by deep industry experience and a shared urgency to act, our expert team is pushing development forward with speed and efficiency.
Today, Unicycive is more than a biotech company. We’re a team united around a single goal: to deliver smarter therapies to patients and providers sooner. We’re not waiting for the future of kidney care—we’re building it.
Our Vision
A world where each of our promising therapies make it into the hands of patients in need.
Our Mission
To transform the lives of under-served patients through the discovery, development, and delivery of new therapies with speed and efficiency.
Our journey
its first technology,
UNI-494
